Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 26, 2013, 73 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $200.03 to $367,425,000.00.

Highlighted Stocks Traded by Insiders:

Sapient Corporation (SAPE) - FREE Research Report

Moore J Stuart who is Director at Sapient Corporation sold 100,000 shares at $15.85 on Sept. 26, 2013. Following this transaction, the Director owned 7.1 million shares meaning that the stake was reduced by 1.39% with the 100,000 share transaction.

The shares most recently traded at $15.82, down $0.03, or 0.19% since the insider transaction. Historical insider transactions for Sapient Corporation go as follows:

  • 4-Week # shares sold: 237,600
  • 12-Week # shares sold: 410,600
  • 24-Week # shares sold: 410,600

The average volume for Sapient Corporation has been 724,800 shares per day over the past 30 days. Sapient Corporation has a market cap of $2.2 billion and is part of the technology sector and computer software & services industry. Shares are up 50.76% year to date as of the close of trading on Thursday.

Sapient Corporation provides various services that enable clients to leverage marketing and technology to transform their businesses in the United States and internationally. It operates in three segments: SapientNitro, Sapient Global Markets, and Sapient Government Services. The company has a P/E ratio of 31.2. Currently there is 1 analyst that rates Sapient Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SAPE - FREE

TheStreet Quant Ratings

rates Sapient Corporation as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Sapient Corporation Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Squinto Stephen P who is EVP, Chief Global Ops. Officer at Alexion Pharmaceuticals sold 304 shares at $112.54 on Sept. 26, 2013. Following this transaction, the EVP, Chief Global Ops. Officer owned 105,186 shares meaning that the stake was reduced by 0.29% with the 304 share transaction.

The shares most recently traded at $115.51, up $2.97, or 2.57% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares sold: 4,737
  • 12-Week # shares sold: 398,838
  • 24-Week # shares sold: 512,401

The average volume for Alexion Pharmaceuticals has been 1.4 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $22.2 billion and is part of the health care sector and drugs industry. Shares are up 21.18% year to date as of the close of trading on Thursday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company has a P/E ratio of 64.5. Currently there are 14 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings

rates Alexion Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Alexion Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Laredo Petroleum Holdings (LPI) - FREE Research Report

Schuyler Jerry R who is Senior Advisor at Laredo Petroleum Holdings sold 50,000 shares at $29.35 on Sept. 26, 2013. Following this transaction, the Senior Advisor owned 396,223 shares meaning that the stake was reduced by 11.21% with the 50,000 share transaction.

The shares most recently traded at $29.71, up $0.36, or 1.2% since the insider transaction. Historical insider transactions for Laredo Petroleum Holdings go as follows:

  • 4-Week # shares sold: 7,000
  • 12-Week # shares sold: 24,000
  • 24-Week # shares sold: 59,000

The average volume for Laredo Petroleum Holdings has been 1.2 million shares per day over the past 30 days. Laredo Petroleum Holdings has a market cap of $4.2 billion and is part of the basic materials sector and energy industry. Shares are up 61.62% year to date as of the close of trading on Thursday.

Laredo Petroleum Holdings, Inc., an independent energy company, focuses on the acquisition, exploration, development, and production of oil and natural gas primarily in the Permian and Mid-Continent regions of the United States. The company has a P/E ratio of 94.7. Currently there are 8 analysts that rate Laredo Petroleum Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LPI - FREE

TheStreet Quant Ratings

rates Laredo Petroleum Holdings as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and disappointing return on equity. Get the full

Laredo Petroleum Holdings Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Amazon.com (AMZN) - FREE Research Report

Wilke Jeffrey A who is Senior Vice President at Amazon.com sold 2,500 shares at $319.02 on Sept. 26, 2013. Following this transaction, the Senior Vice President owned 50,433 shares meaning that the stake was reduced by 4.72% with the 2,500 share transaction.

The shares most recently traded at $315.37, down $3.65, or 1.16% since the insider transaction. Historical insider transactions for Amazon.com go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares sold: 1.0 million
  • 24-Week # shares sold: 1.0 million

The average volume for Amazon.com has been 2.5 million shares per day over the past 30 days. Amazon.com has a market cap of $143.5 billion and is part of the services sector and retail industry. Shares are up 25.22% year to date as of the close of trading on Thursday.

Amazon.com, Inc. operates as an online retailer in North America and internationally. The company operates in two segments, North America and International. Currently there are 24 analysts that rate Amazon.com a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMZN - FREE

TheStreet Quant Ratings

rates Amazon.com as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full

Amazon.com Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 15,000 shares at $8.73 on Sept. 26, 2013. Following this transaction, the CEO & Chairman owned 136.8 million shares meaning that the stake was reduced by 0.01% with the 15,000 share transaction.

The shares most recently traded at $8.64, down $0.09, or 1.09% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 24-Week # shares bought: 4,300

The average volume for Opko Health has been 2.7 million shares per day over the past 30 days. Opko Health has a market cap of $3.5 billion and is part of the health care sector and health services industry. Shares are up 81.5% year to date as of the close of trading on Thursday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings

rates Opko Health as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share. Get the full

Opko Health Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by

Zacks Investment Research

null